Insulin, leptin, and adiponectin receptors in colon: regulation relative to differing body adiposity independent of diet and in response to dimethylhydrazine.
Obesity has recently become a focus of research to elucidate diet and lifestyle factors as important risk factors for colon cancer. Altered levels of insulin, leptin, and adiponectin have been identified as potential candidates increasing colon cancer risk within the prevailing obesogenic environment. There has been considerable research to characterize signaling via these hormones in the brain, liver, and adipose tissue; however, very little is known of their emerging role in peripheral signaling, particularly in epithelial tissues. This study profiles insulin, leptin, and adipokine receptors in the rat colon, revealing novel microanatomical location of these receptors and thereby supporting a potential role in regulating colonic tissue. Potential involvement of insulin, leptin, and adiponectin receptors in increased risk of colon cancer was investigated using Sprague-Dawley rats, either resistant or susceptible to diet-induced obesity. Regulation of insulin, leptin, and adiponectin receptors as a consequence of differing levels of adiposity was assessed regionally in the colon in response to treatment with the chemical carcinogen 1,2-dimethylhydrazine (DMH). However, significantly increased fat mass, increased levels of plasma insulin, leptin, and triglycerides, previously associated with an increased risk of colon cancer, were not associated with promotion of precancerous lesions in the experimental rats or deregulation of insulin, leptin, or adiponectin receptors. These findings do not support a direct link between the deregulation of insulin and adipokine levels observed in obese rats and an increased risk of colon carcinogenesis.
Drew
Janice E
JE
Gut Health Division, Rowett Research Institute, Greenburn Rd., Bucksburn, Aberdeen, AB21 9SB, Scotland, UK. jed@rowett.ac.uk
Farquharson
Andrew J
AJ
Padidar
Sara
S
Duthie
Garry G
GG
Mercer
Julian G
JG
Arthur
John R
JR
Morrice
Philip C
PC
Barrera
Lawrence N
LN
D019813:1,2-Dimethylhydrazine / Q000494:pharmacology*; D052242:Adiponectin / Q000378:metabolism; D000273:Adipose Tissue / Q000503:physiopathology; D000818:Animals; D003106:Colon / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009765:Obesity / Q000503:physiopathology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011972:Receptor, Insulin / Q000502:physiology*; D054419:Receptors, Adiponectin / Q000502:physiology*; D054411:Receptors, Leptin / Q000502:physiology*
D052242:Adiponectin; D054419:Receptors, Adiponectin; D054411:Receptors, Leptin; C504339:adiponectin receptor 1, rat; C506573:adiponectin receptor 2, rat; D011972:Receptor, Insulin; D019813:1,2-Dimethylhydrazine